# NCT03975647 (NCT03975647)

> A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03975647
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Conditions: HER2-positive Breast Cancer
- Interventions: tucatinib; placebo; T-DM1
- Enrollment: 466
- Primary outcome: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment

## Commentary we found

- X threads: 41
- YouTube: 14
- Podcasts: 11
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03975647

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03975647", "email": "<work email>"}; the inbox owner confirms by the emailed link.